Effects of calcineurin inhibitors on an in vitro assay for chronic urticaria

Clinical and Experimental Allergy

Volumn 35, Issue 5, 2005, Pages 554-559

  Marsland, A M ^a   Soundararajan, S ^a   Joseph, K ^a   Kaplan, Allen P ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Ascomycin; Calcineurin; Ciclosporin; Immunosuppression; Methotrexate; Pimecrolimus; Urticaria

Indexed keywords

ASCOMYCIN; CALCINEURIN INHIBITOR; COMPLEMENT COMPONENT C5A; CYCLOSPORIN A; DIPHENHYDRAMINE; HISTAMINE; HYDROXYZINE; IMMUNOGLOBULIN E RECEPTOR; IMMUNOGLOBULIN G ANTIBODY; METHOTREXATE;

ARTICLE; BASOPHIL; CHRONIC URTICARIA; CROSS LINKING; DOSE RESPONSE; DRUG EFFECT; HISTAMINE RELEASE; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LEUKOCYTE; MAST CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

BASOPHILS; CALCINEURIN; CELLS, CULTURED; CHRONIC DISEASE; COMPLEMENT C5A; CYCLOSPORINE; DIPHENHYDRAMINE; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HISTAMINE H1 ANTAGONISTS; HISTAMINE RELEASE; HUMANS; HYDROXYZINE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES; METHOTREXATE; RECURRENCE; TACROLIMUS; URTICARIA;

EID: 20044386002     PISSN: 09547894     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2222.2005.02242.x     Document Type: Article

References (21)

1. Kaplan AP. Clinical practice. Chronic urticaria and angioedema. N Engl J Med 2002; 346:175-9.
2. Grattan CE, Sabroe RA, Greaves MW. Chronic urticaria. J Am Acad Dermatol 2002; 46:645-57; quiz 57-60.
3. Hide M, Francis DM, Grattan CE, Hakimi J, Kochan JP, Greaves MW. Autoantibodies against the high-affinity IgE receptor as a cause of histamine release in chronic urticaria. N Engl J Med 1993; 328:1599-604.
4. Sabroe RA, Seed PT, Francis DM, Barr RM, Black AK, Greaves MW. Chronic idiopathic urticaria: comparison of the clinical features of patients with and without anti-FcepsilonRI or anti-IgE autoantibodies. J Am Acad Dermatol 1999; 40:443-50.
5. Bagenstose SE, Levin L, Bernstein JA. The addition of zafirlukast to cetirizine improves the treatment of chronic urticaria in patients with positive autologous serum skin test results. J Allergy Clin Immunol 2004; 113:134-40.
6. Pacor ML, Di Lorenzo G, Corrocher R. Efficacy of leukotriene receptor antagonist in chronic urticaria. A double-blind, placebo-controlled comparison of treatment with montelukast and cetirizine in patients with chronic urticaria with intolerance to food additive and/or acetylsalicylic acid. Clin Exp Allergy 2001; 31:1607-14.
7. Berroeta L, Clark C, Ibbotson SH, Ferguson J, Dawe RS. Narrow-band (TL-01) ultraviolet B phototherapy for chronic urticaria. Clin Exp Dermatol 2004; 29:97-8.
8. Grattan CE, Francis DM, Slater NG, Barlow RJ, Greaves MW. Plasmapheresis for severe, unremitting, chronic urticaria. Lancet 1992; 339:1078-80.
9. O'Donnell BF, Barr RM, Black AK et al. Intravenous immunoglobulin in autoimmune chronic urticaria. Br J Dermatol 1998; 138:101-6.
10. Grattan CE, O'Donnell BF, Francis DM et al. Randomized double-blind study of cyclosporin in chronic 'idiopathic' urticaria. Br J Dermatol 2000; 143:365-72.
11. Kikuchi Y, Kaplan AP. Mechanisms of autoimmune activation of basophils in chronic urticaria. J Allergy Clin Immunol 2001; 107:1056-62.
12. Plath KE, Grabbe J, Gibbs BF. Calcineurin antagonists differentially affect mediator secretion, p38 mitogen-activated protein kinase and extracellular signal-regulated kinases from immunologically activated human basophils. Clin Exp Allergy 2003; 33:342-50.
13. Kikuchi Y, Kaplan AP. A role for C5a in augmenting IgG-dependent histamine release from basophils in chronic urticaria. J Allergy Clin Immunol 2002; 109:114-8.
14. Zuberbier T, Chong SU, Grunow K et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001; 108: 275-80.
15. Soundararajan S, Joseph K, Kaplan AP. Autoimmune chronic urticaria is caused by IgG3 and IgG1 autoantibodies to the alpha subunit of the IgE receptor. J Allergy Clin Immunol 2004; 113:885.
16. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12:618-22.
17. Shupack JL, Kenny C, Jondreau L, Eckman I, Gropper C, Stiller MJ. Decreased peripheral blood eosinophil counts in severe psoriatic patients treated with low-dose cyclosporine A. Dermatology 1992; 185:202-4.
18. Ying S, Kikuchi Y, Meng Q, Kay AB, Kaplan AP. TH1/TH2 cytokines and inflammatory cells in skin biopsy specimens from patients with chronic idiopathic urticaria: comparison with the allergen-induced late-phase cutaneous reaction. J Allergy Clin Immunol 2002; 109:694-700.
19. Wolff K, Stuetz A. Pimecrolimus for the treatment of inflammatory skin disease. Expert Opin Pharmacother 2004; 5:643-55.
20. Scott G, Osborne SA, Greig G et al. Pharmacokinetics of pimecrolimus, a novel nonsteroid anti-inflammatory drug, after single and multiple oral administration. Clin Pharmacokinet 2003; 42:1305-14.
21. Rappersberger K, Komar M, Ebelin ME et al. Pimecrolimus identifies a common genomic anti-inflammatory profile, is clinically highly effective in psoriasis and is well tolerated. J Invest Dermatol 2002; 119:876-87.